Paroxysmal slow cortical activity in Alzheimer's disease and epilepsy is associated with blood-brain barrier dysfunction

DZ Milikovsky, J Ofer, VV Senatorov Jr… - Science Translational …, 2019 - science.org
DZ Milikovsky, J Ofer, VV Senatorov Jr, AR Friedman, O Prager, L Sheintuch, N Elazari…
Science Translational Medicine, 2019science.org
A growing body of evidence shows that epileptic activity is frequent but often undiagnosed in
patients with Alzheimer's disease (AD) and has major therapeutic implications. Here, we
analyzed electroencephalogram (EEG) data from patients with AD and found an EEG
signature of transient slowing of the cortical network that we termed paroxysmal slow wave
events (PSWEs). The occurrence per minute of the PSWEs was correlated with level of
cognitive impairment. Interictal (between seizures) PSWEs were also found in patients with …
A growing body of evidence shows that epileptic activity is frequent but often undiagnosed in patients with Alzheimer’s disease (AD) and has major therapeutic implications. Here, we analyzed electroencephalogram (EEG) data from patients with AD and found an EEG signature of transient slowing of the cortical network that we termed paroxysmal slow wave events (PSWEs). The occurrence per minute of the PSWEs was correlated with level of cognitive impairment. Interictal (between seizures) PSWEs were also found in patients with epilepsy, localized to cortical regions displaying blood-brain barrier (BBB) dysfunction, and in three rodent models with BBB pathology: aged mice, young 5x familial AD model, and status epilepticus–induced epilepsy in young rats. To investigate the potential causative role of BBB dysfunction in network modifications underlying PSWEs, we infused the serum protein albumin directly into the cerebral ventricles of naïve young rats. Infusion of albumin, but not artificial cerebrospinal fluid control, resulted in high incidence of PSWEs. Our results identify PSWEs as an EEG manifestation of nonconvulsive seizures in patients with AD and suggest BBB pathology as an underlying mechanism and as a promising therapeutic target.
AAAS